- Harrow Health Inc. ( NASDAQ: HROW ) fell 4.8% after a new short report from Bonitas Research about the eyecare pharmaceutical company.
- Bonitas claims that company has issues with "risks disclosures" and "quality control standards," according to the report. Bonitas said it's short Harrow Health.
- Harrow Health ( HROW ) short interest is 4.7%.
- Harrow Health ( HROW ) didn't immediately respond to Seeking Alpha request for comment.
- In December Harrow Health announced a deal with Novartis to sell U.S. rights for eyecare products.
For further details see:
Harrow Health drops on new short report from Bonitas Research